ProBio Announces Completion of NMPA Pre-Approval Inspection at Its China Manufacturing Facility; Providence Medical Secures FDA Approval for CORUS PCSS 3D-T Spinal Device; Sony Semiconductor Solutions Launches Compact Image Sensor for Single-Use Endoscopes; Ping An Launches China’s First Comprehensive Alzheimer’s Disease Brain Health Management Program; Geneos Therapeutics Advances Personalized DNA Immunotherapy for Liver Cancer into Phase 2; Medtronic Reports Positive Real-World Data for Sphere-9 and PulseSelect PFA

ProBio Completed NMPA Pre-Approval Inspection at Its Biologics Manufacturing Facility in China 

On 21 October 2026, ProBio Inc. announced the successful completion of a pre-approval inspection conducted by China’s National Medical Products Administration (NMPA) at its biologics manufacturing facility in Nanjing, China. The milestone demonstrated the facility’s manufacturing readiness, quality systems, and compliance preparedness for the inspected product and manufacturing process. ProBio had supported its customer from the Investigational New Drug (IND) stage through Biologics License Application (BLA) submission, providing integrated development, process optimization, technology transfer, and Good Manufacturing Practice (GMP) manufacturing services. 

The company has continued investing in its manufacturing infrastructure, analytical capabilities, quality systems, and operational capacity to support biologic medicines through clinical development and commercialization. The successful inspection strengthened ProBio’s position as a contract research, development, and manufacturing partner for biopharmaceutical companies seeking scalable manufacturing capabilities and regulatory support.

“This milestone reflects the strength of our quality organization and biologics manufacturing operations, as well as the investments we have made to build a reliable platform for our customers,” said Allen Guo, CEO of ProBio. “As our customers advance programs toward commercialization, they need a manufacturing partner with the capabilities, quality systems and operational discipline to support increasingly demanding regulatory requirements. This achievement reinforces our commitment to being that partner.”

As per DelveInsight’s “Biologics Contract Manufacturing Market Report,” the global biologics contract manufacturing market was valued at USD 23,240.99 million in 2024, growing at a CAGR of 9.39% during the forecast period from 2025 to 2032 to reach USD 47,494.63 million by 2032. The rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is fueling the demand for biologics, leading pharmaceutical companies to increase outsourcing to contract manufacturers for large-scale production. Simultaneously, a robust pipeline of biologics, including monoclonal antibodies, vaccines, and biosimilars, requires flexible manufacturing solutions to meet growing market needs efficiently. Advancements in biotechnology and biomedical science techniques such as recombinant DNA technology and improved expression systems are enabling faster development cycles, making contract manufacturing a preferred choice for scalability. Furthermore, growing product development activities globally, driven by small and mid-sized biotech firms and major pharmaceutical players, are enhancing collaborations with CMOs and CDMOs to accelerate time-to-market while maintaining cost efficiency. Together, these factors are propelling the biologics contract manufacturing market forward, addressing the need for high-quality, large-scale production with enhanced flexibility and expertise during the forecast period from 2025 to 2032.

FDA Approved Providence Medical’s CORUS PCSS 3D-T Spinal Device 

On 13 October 2026, Providence Medical Technology announced that it had received FDA 510(k) clearance for its CORUS Posterior Cervical Stabilization System 3D-T. The next-generation implant combined a 3D-manufactured porous titanium structure with an established posterior cervical stabilization design to support bone ingrowth and spinal fusion. The device was intended to immobilize and stabilize spinal segments as an adjunct to posterior cervical fusion in patients with cervical degenerative disc disease. Its design incorporated integrated screw fixation and was developed to support fusion procedures involving the cervical spine. The company planned to showcase the system at the North American Spine Society’s 2026 Annual Meeting in San Antonio, Texas. The regulatory clearance strengthened Providence Medical Technology’s spinal implant portfolio and highlighted continued innovation in cervical stabilization, implant design, and surgical treatment for degenerative spinal conditions.

As per DelveInsight’s “Spinal Implants Market Report,” the global spinal implants market was valued at USD 14,324.12 million in 2024, growing at a CAGR of 5.50% during the forecast period from 2025 to 2032 to reach USD 21,899.24 million by 2032. The rising cases of spinal disorders, particularly among aging populations, have significantly increased the demand for corrective surgical interventions. Simultaneously, the surge in sports-related and accident-induced spinal injuries is fueling the need for advanced implantable solutions. Moreover, there is a growing preference for non-fusion and motion preservation devices that maintain spinal mobility and enhance patient outcomes, especially among younger and more active individuals. Coupled with this is the uptick in product development activities and technological innovations by key market players globally, which is expanding the range of available solutions and improving surgical success rates. Together, these trends are accelerating the adoption of Spinal Implants and driving the overall market during the forecast period from 2025 to 2032.

Sony Semiconductor Solutions Introduced a Miniature Image Sensor for Single-Use Medical Endoscopes 

On 21 October 2026, Sony Semiconductor Solutions Corporation announced the IMX742, a compact CMOS image sensor designed for single-use medical endoscopes. Measuring just 1 mm × 1 mm, the sensor delivered approximately 0.51 megapixels and supported digital image transmission over a 5-meter cable. 

It also enabled imaging at up to 60 frames per second, helping produce clearer images with reduced noise, particularly in low-light conditions inside the body. The technology was designed to support thinner endoscope cameras, including those used in bronchoscopes and ureteroscopes, while improving image visibility and flexibility in system design. Sony planned to begin shipping product samples in November 2026, expanding its medical imaging sensor portfolio into the growing single-use endoscope segment.

As per DelveInsight’s “Endoscopes Market Report,” the global endoscopes market was valued at USD 12.95 billion in 2023, growing at a CAGR of 6.05% during the forecast period from 2024 to 2030 to reach USD 18.32 billion by 2030. The increase in demand for endoscopes is primarily attributed to the increasing prevalence of chronic disease which require the use of endoscopes for diagnosis, such as some gastrointestinal diseases like irritable bowel syndrome (IBD), gastroesophageal reflux disease (GERD), peptic ulcer disease, and crohn’s disease, increase in number of geriatric population who are more prone to chronic ailments, increasing awareness and demand of minimally invasive surgeries and no blood loss surgery, and rise in technological advancements in endoscopes like image magnification, high-definition optical systems and digital imaging are anticipated to bolster the market, thereby contributing to the growth of the endoscopes market during the forecast period from 2024-2030.

Ping An Introduced China’s First Comprehensive Brain Health Management Program for Alzheimer’s Disease  

On 21 October 2026, Ping An Insurance introduced a comprehensive brain health service management program in China to support the early screening, diagnosis, treatment, rehabilitation, and long-term care of patients with Alzheimer’s disease. The initiative, developed with Ping An Good Doctor and other healthcare and insurance partners, integrated cognitive assessments, genetic testing, biomarker screening, specialist consultations, digital rehabilitation, home safety monitoring, and insurance-based financial support. 

The company also launched a charitable initiative across 30 communities in Beijing to provide regular early screening and one year of medication assistance to eligible patients facing financial difficulties, supported by a contribution of RMB 1 million. The program addressed challenges associated with delayed diagnosis, rising care costs, and limited access to specialist services. Ping An also outlined plans to expand its brain health services to include stroke, Parkinson’s disease, and depression, strengthening the integration of healthcare delivery, preventive services, and insurance coverage.

Mr. Xi Tongzhuan, deputy general manager of Ping An Good Doctor, said that the brain health program brings together Ping An’s “integrated finance + health and senior care” strategy, leading insurance expertise, extensive medical service network, and its medical large language model (LLM) platform. The program marks a further step in integrating health care and insurance and offers a market-based approach to Alzheimer’s care throughout the course of the disease.

According to DelveInsight’s “Alzheimer’s Disease Diagnostic Market Report”, the global Alzheimer’s disease (AD) diagnostic market will grow at a CAGR of 10.97% during the forecast period from 2024 to 2030. The Alzheimer’s disease (AD) diagnostic market is observing optimistic market growth due to factors such as the rise in regulatory approvals for Alzheimer’s disease (AD) diagnostics across the globe. Further, the rising prevalence of head injuries owing to the accidents, workplace injuries, and others, and the rise in geriatric population will increase the prevalence of Alzheimer disease, thereby increasing the demand of the Alzheimer disease diagnostic devices across the globe. Additionally, the increasing research and development of novel biomarkers, presence of key players in the market, increasing product launches and approvals, and others will create a requirement for Alzheimer disease diagnostics in the upcoming years. Therefore, the market for Alzheimer’s disease (AD) diagnostics is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Geneos Therapeutics Initiated Phase 2 Trial of Personalized DNA Immunotherapy for Liver Cancer 

On 21 October 2026, Geneos Therapeutics announced the initiation of its IMPACT31 Phase 2 randomized clinical trial evaluating GNOS-PV02, a personalized neoantigen-targeted DNA immunotherapy, in patients with high-risk hepatocellular carcinoma (HCC) following surgical removal of the tumor. The global, multicenter study planned to enroll 90 patients and compare the investigational treatment with active surveillance to assess its potential to reduce cancer recurrence. 

The therapy used genetic information from individual tumors to identify neoantigens and develop patient-specific DNA vaccines designed to stimulate immune cells against cancer cells while sparing healthy tissues. The company also appointed Julie Rosenberg, MD, as Chief Medical Officer to strengthen its clinical development and leadership capabilities. The trial represented a further step in Geneos Therapeutics’ efforts to advance personalized cancer immunotherapies and address the risk of recurrence among patients with liver cancer.

“We are thrilled to welcome Julie to our leadership team to drive the IMPACT31 trial and advance the development of Geneos’ tumor-agnostic immunotherapy platform and clinical pipeline. Her experience and well-developed network in clinical development within biopharma will be invaluable in the coming years as Geneos advances toward late-stage clinical development,” said Niranjan Sardesei, Ph.D., President & CEO of Geneos. “We have reported clinical safety and efficacy in our early Phase 1/2 trials, in two distinct cancers, by treating patients with advanced HCC who failed or were intolerant to first-line therapy and, also in the adjuvant setting in glioblastoma (brain cancer). These are two hard-to-treat, immune-excluded, cold cancers, which have historically proved unresponsive to immunotherapy. We are excited to bring the possibility of long-term clinical benefit to high-risk HCC patients in this randomized controlled trial.”

As per DelveInsight’s “Cancer Vaccines Market Report,” the cancer vaccines market is estimated at USD 11.40 billion in 2025 and is projected to reach USD 33.60 billion by 2034. Growth is anchored in the rising global cancer burden, the expanding clinical and commercial success of therapeutic neoantigen and mRNA-based candidates, and sustained public-health investment in preventive HPV and hepatitis B vaccination programs. The global Cancer Vaccines market is growing at a CAGR of 12.7% during the forecast period from 2026 to 2034.

Medtronic Reported Positive Real-World Results for Sphere-9 Catheter and PulseSelect PFA System 

On 22 October 2026, Medtronic announced positive findings from global real-world registries evaluating its Sphere-9 catheter and PulseSelect pulsed field ablation (PFA) system at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting. The APEX registry evaluated 1,050 patients with atrial fibrillation treated using the Sphere-9 catheter, reporting a 1.1% major complication rate. 

The REAL PULSE registry included 1,160 atrial fibrillation patients treated with the PulseSelect system and demonstrated a 100% acute procedural success rate, with an acute major complication rate of 0.09%. Additionally, a European APEX registry analysis of 46 patients undergoing ablation for ventricular tachycardia reported 87% acute success and an estimated 75% freedom from recurrence at six months. These findings strengthened the clinical evidence supporting Medtronic’s cardiac ablation technologies and highlighted their potential to expand treatment options for patients with cardiac arrhythmias.

“These favorable results reinforce our confidence in the safety and performance of our ablation technologies worldwide. It is very encouraging to see physicians’ positive response and real-world evidence that supports effective, safe, and efficient care for patients with a wide range of arrhythmias,” said Khaldoun Tarakji, M.D., MPH, Vice President and Chief of Science, Research and Technology, Electrophysiology Therapies at Medtronic.

According to DelveInsight’s “Cardiac Ablation Devices Market Report,” the global cardiac ablation devices market is expected to increase from USD 3,832.19 million in 2024 to USD 10,317.88 million by 2032, reflecting strong and sustained growth. The global cardiac ablation devices market is growing at a CAGR of 13.25% during the forecast period from 2025 to 2032. The cardiac ablation devices market is witnessing strong growth, driven by the rising prevalence of cardiovascular disorders, especially atrial fibrillation, and growing patient preference for minimally invasive procedures. Advances in technology, including radiofrequency and cryoablation systems, contact force-sensing catheters, and pulsed field ablation, are improving precision, safety, and outcomes. With manufacturers developing next-generation platforms integrating imaging, mapping, and AI guidance, these factors are expected to sustain robust market expansion in the coming years.